Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Krystal Biotech announced their participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting where they will present new preclinical data on their HSV-1 based vector platform for back of the eye gene delivery. The poster presentation will focus on localized delivery to the posterior of the eye, with details about the presenter, date, time, and abstract number. The poster will be available both at the conference and online on the Investor section of the Company's website.
Krystal Biotech showcasing new preclinical data at a prestigious industry event demonstrates the Company's commitment to research and innovation.
The HSV-1 based vector platform for back of the eye gene delivery shows promising potential for addressing unmet medical needs in the ophthalmology field.
- None.
PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data highlighting the potential of the Company’s HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington.
Poster presentation details are as follows:
Title: An HSV-1-Based Vector Platform for Localized Delivery to the Posterior of the Eye
Presenter: Haley Nicole Cartwright
Date and Time: May 7, 2024 from 3:30PM to 5:15PM PT
Posterboard Number: B0022
Abstract Number: 3978 - B0022
The poster will be available to conference attendees. Following the presentation, the poster will also be available to view online on the Investor section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com
FAQ
What is Krystal Biotech presenting at the ARVO 2024 Annual Meeting?
When and where will the ARVO 2024 Annual Meeting take place?
Where can the poster presentation be viewed?
